KR20170135966A - 게놈 dna를 변형시키기 위한 방법 및 조성물 - Google Patents

게놈 dna를 변형시키기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20170135966A
KR20170135966A KR1020177032721A KR20177032721A KR20170135966A KR 20170135966 A KR20170135966 A KR 20170135966A KR 1020177032721 A KR1020177032721 A KR 1020177032721A KR 20177032721 A KR20177032721 A KR 20177032721A KR 20170135966 A KR20170135966 A KR 20170135966A
Authority
KR
South Korea
Prior art keywords
cell
cells
dna
sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177032721A
Other languages
English (en)
Korean (ko)
Inventor
린홍 리
마드수단 페쉬와
Original Assignee
맥스시티 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맥스시티 인코포레이티드 filed Critical 맥스시티 인코포레이티드
Priority to KR1020257013453A priority Critical patent/KR20250058073A/ko
Publication of KR20170135966A publication Critical patent/KR20170135966A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020177032721A 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물 Ceased KR20170135966A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257013453A KR20250058073A (ko) 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146618P 2015-04-13 2015-04-13
US62/146,618 2015-04-13
PCT/US2016/027253 WO2016168275A1 (en) 2015-04-13 2016-04-13 Methods and compositions for modifying genomic dna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257013453A Division KR20250058073A (ko) 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20170135966A true KR20170135966A (ko) 2017-12-08

Family

ID=55806847

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177032721A Ceased KR20170135966A (ko) 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물
KR1020257013453A Pending KR20250058073A (ko) 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257013453A Pending KR20250058073A (ko) 2015-04-13 2016-04-13 게놈 dna를 변형시키기 위한 방법 및 조성물

Country Status (8)

Country Link
US (1) US11608511B2 (enExample)
EP (1) EP3283635B1 (enExample)
JP (1) JP6885876B2 (enExample)
KR (2) KR20170135966A (enExample)
CN (1) CN107980059B (enExample)
CA (1) CA2982759C (enExample)
ES (1) ES2926467T3 (enExample)
WO (1) WO2016168275A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
KR102424850B1 (ko) 2017-06-30 2022-07-22 인스크립타 인코포레이티드 자동 세포 처리 방법, 모듈, 기기 및 시스템
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
KR20250111214A (ko) 2017-09-01 2025-07-22 론차 콜로그네 게엠베하 엔드-투-엔드 세포 요법의 자동화
AU2018338990B2 (en) 2017-09-30 2022-06-23 Inscripta, Inc. Flow through electroporation instrumentation
EP3775159A4 (en) 2018-03-29 2022-01-19 Inscripta, Inc. AUTOMATED REGULATION OF CELL GROWTH RATES FOR INDUCTION AND TRANSFORMATION
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
WO2020081149A2 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
US12460174B2 (en) 2018-09-28 2025-11-04 Octane Biotech Inc. Magnetic separation
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CA3123449A1 (en) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
CA3123314A1 (en) 2018-12-21 2020-06-25 Octane Biotech Inc. Carousel for modular biologic production units
CN113498432A (zh) 2019-02-08 2021-10-12 隆萨沃克斯维尔股份有限公司 用于自动化生物反应器的细胞浓缩方法和装置
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CN113939593A (zh) 2019-06-06 2022-01-14 因思科瑞普特公司 用于递归的核酸指导的细胞编辑的处治
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
IL292409A (en) 2019-10-24 2022-06-01 Octane Biotech Inc A cell culture chamber with enhanced cell contact surfaces
KR20220097457A (ko) 2019-11-11 2022-07-07 론자 워커스빌 아이엔씨. 자동화된 세포 처리를 위한 품질 관리 방법
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
US10883095B1 (en) 2019-12-10 2021-01-05 Inscripta, Inc. Mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
CN114829607A (zh) 2019-12-18 2022-07-29 因思科瑞普特公司 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2021154706A1 (en) 2020-01-27 2021-08-05 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
CN112195193A (zh) * 2020-09-30 2021-01-08 上海交通大学 单链dna在基因转染中的应用
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
EP0690671B1 (en) 1993-03-23 2004-08-04 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
JPH0844143A (ja) 1993-06-29 1996-02-16 Toshiba Corp 帯電装置並びに該帯電装置を備えた画像形成装置
US6074605A (en) 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
JP3859709B2 (ja) 1995-03-10 2006-12-20 マックスサイト インコーポレイテッド フローエレクトロポレーションチャンバー及び方法
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
JP4031033B2 (ja) * 1995-05-04 2008-01-09 アメリカ合衆国 Ｔ細胞の改良トランスフェクション法
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
DE69835145T2 (de) 1997-02-28 2007-06-14 Kirin Beer K.K. Transgene Mäuse die ein menschliches Antikörper exprimieren
AU2001289104A1 (en) 2000-09-15 2002-03-26 Deltagen, Inc. Methods of producing cells and animals comprising targeted gene modifications
WO2002026966A2 (en) 2000-09-29 2002-04-04 Ecole Polytechnique Federale De Lausanne Transfection using plasmid preparations
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
EP1456345B1 (en) 2001-08-22 2016-07-20 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
AU2003277109A1 (en) 2002-09-30 2004-04-23 Maxcyte, Inc. Apparatus and method for streaming electroporation
JP2006518219A (ja) 2003-02-18 2006-08-10 マックスサイト インコーポレーティッド 電気穿孔法による細胞への抗原の負荷方法
US8409861B2 (en) * 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
DK1766057T3 (en) 2004-05-12 2015-03-02 Maxcyte Inc Methods and devices related to a regulated flowelektroporationskammer
SG163592A1 (en) 2004-07-23 2010-08-30 Immunomedics Inc Methods and compositions for increasing longevity and protein yield from a cell culture
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
WO2007030674A2 (en) 2005-09-07 2007-03-15 Maxcyte, Inc. Use of nucleases to improve viability and enhance transgene expression in transfected cells
KR101087809B1 (ko) 2006-04-10 2011-11-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단일 세포 및 콜로니의 수집을 위한 시스템
CA2687688C (en) 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
WO2012001073A2 (en) 2010-07-01 2012-01-05 Glaxo Group Limited Improved method for selecting high producing cell lines
EP3489359A1 (en) 2010-07-23 2019-05-29 Sigma Aldrich Co. LLC Genome editing using targeting endonucleases and single-stranded nucleic acids
CA2852955C (en) 2011-10-27 2021-02-16 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
WO2013139994A1 (en) 2012-03-23 2013-09-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) A novel method of producing an oocyte carrying a modified target sequence in its genome
BR112014027813A2 (pt) * 2012-05-07 2017-08-08 Dow Agrosciences Llc métodos e composições para integração de transgenes direcionada mediada por nuclease
CN104540382A (zh) 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
CN102839214A (zh) 2012-09-06 2012-12-26 许汉鹏 筛选真核细胞基因组内特定基因调控相关机制和分子的方法
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
EP2970915B1 (en) 2013-03-15 2019-08-14 Maxcyte, Inc. Methods and compositions for generating stable transfected cells
CN103224947B (zh) * 2013-04-28 2015-06-10 陕西师范大学 一种基因打靶系统
DK3004337T3 (da) 2013-05-29 2017-11-13 Cellectis Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system
ES2883131T3 (es) * 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
ES2962509T3 (es) 2014-04-14 2024-03-19 Maxcyte Inc Métodos y composiciones para modificar ADN genómico
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification

Also Published As

Publication number Publication date
CA2982759A1 (en) 2016-10-20
WO2016168275A1 (en) 2016-10-20
JP2018512162A (ja) 2018-05-17
CN107980059B (zh) 2022-11-11
JP6885876B2 (ja) 2021-06-16
US11608511B2 (en) 2023-03-21
EP3283635A1 (en) 2018-02-21
ES2926467T3 (es) 2022-10-26
EP3283635B1 (en) 2022-07-06
CN107980059A (zh) 2018-05-01
CA2982759C (en) 2025-05-20
KR20250058073A (ko) 2025-04-29
US20180112235A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
JP7209671B2 (ja) ゲノムｄｎａを改変するための方法および組成物
JP6885876B2 (ja) ゲノムｄｎａを改変するための方法および組成物
JP2022153470A (ja) ゲノムｄｎａを改変するための方法および組成物
US12130281B2 (en) Gene editing through microfluidic delivery
WO2019202099A1 (en) Enrichment of genome-edited cells
EP4342983A1 (en) Method for modifying cell
CN114728021B (zh) 同种异体t细胞和其产生方法
EP4574979A1 (en) Engineered immune cell and preparation method therefor
WO2022125671A1 (en) Delivery of molecules to cells using trogocytosis and engineered cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231005

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240628

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241125

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20241223

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20241223

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250423